1
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Akiyama T, Dass CR and Choong PF: Novel
therapeutic strategy for osteosarcoma targeting osteoclast
differentiation, bone-resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 7:3461–3469. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Townsley FM, Aristarkhov A, Beck S,
Hershko A and Ruderman JV: Dominant-negative cyclin-selective
ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase.
Proc Natl Acad Sci USA. 94:2362–2367. 1997. View Article : Google Scholar : PubMed/NCBI
|
6
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M,
Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2
ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173.
2003.PubMed/NCBI
|
7
|
Lin Y, Hwang WC and Basavappa R:
Structural and functional analysis of the human mitotic-specific
ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 277:21913–21921.
2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Aristarkhov A, Eytan E, Moghe A, Admon A,
Hershko A and Ruderman JV: E2-C, a cyclin-selective ubiquitin
carrier protein required for the destruction of mitotic cyclins.
Proc Natl Acad Sci USA. 93:4294–4299. 1996. View Article : Google Scholar : PubMed/NCBI
|
9
|
Rape M, Reddy SK and Kirschner MW: The
processivity of multiubiquitination by the APC determines the order
of substrate degradation. Cell. 124:89–103. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hao Z, Zhang H and Cowell J:
Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in
tumorigenesis, and potential as a biomarker. Tumour Biol.
33:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Xie C, Powell C, Yao M, Wu J and Dong Q:
Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker. Int
J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
van Ree JH, Jeganathan KB, Malureanu L and
van Deursen JM: Overexpression of the E2 ubiquitin-conjugating
enzyme UbcH10 causes chromosome missegregation and tumor formation.
J Cell Biol. 188:83–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Jiang L, Bao Y, Luo C, et al: Knockdown of
ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA
interference inhibits glioma cell proliferation and enhances cell
apoptosis in vitro. J Cancer Res Clin Oncol. 136:211–217. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen SM, Jiang CY, Wu JY, et al: RNA
interference-mediated silencing of UBCH10 gene inhibits colorectal
cancer cell growth in vitro and in vivo. Clin Exp Pharmacol
Physiol. 37:525–529. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Pallante P, Malapelle U, Berlingieri MT,
et al: UbcH10 overexpression in human lung carcinomas and its
correlation with EGFR and p53 mutational status. Eur J Cancer.
49:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kleiner DE and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43:Suppl. S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI
|
18
|
Davies KJ: The complex interaction of
matrix metalloproteinases in the migration of cancer cells through
breast tissue stroma. Int J Breast Cancer. 2014:8390942014.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Wang J, Shi Q, Yuan TX, et al: Matrix
metalloproteinase 9 (MMP-9) in osteosarcoma: review and
meta-analysis. Clin Chim Acta. 433:225–231. 2014. View Article : Google Scholar : PubMed/NCBI
|